Chlamydia Vaccine: Is Development Worth the High Cost?
MARCH 06, 2017
At AAAAI 2017, Jared Ditkowsky, MD, of SUNY Downstate, spoke with MD Magazine about the connotations surrounding the development of a potential vaccine for Chlamydia trachomatis (C. trachomatis), the infection causing chlamydia - one of the most common bacterial sexually transmitted infections in the United States.
While there is no vaccine currently on the market, this is something people have been working towards for three or four decades now, and there've been some issues with vaccine development. Ditkowsky explained, "Part of the issue is that the pathology associated with chlamydia is largely based on the host immune response. When you're infected with chlamydia, your actual immune response causes a lot of the disease, so when you look to vaccinate against chlamydia, you need to vaccinate in a way your body can prevent infection, but doesn't respond in a way that it actually harms your body." Ditkowsky continued that researchers have been working on it a lot recently; they think they've discovered the specific immune response they're looking for to protect without causing harm. Now, they're looking for a way to elicit that appropriately in people. There're a lot of vaccines in development, at least one in phase 1 clinical trials.